SCHEMBL22808237

SCHEMBL22808237

CC(C)NC(=O)c1cc(C(=O)NC(C)C)n(C)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
MLYCD O95822 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HPGD P15428 2/20 0.40
BRD4 O60885 1/20 0.39
CYP1A2 P05177 3/20 0.38
CYP2C19 P33261 3/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
ALOX15 P16050 1/20 0.38
PTGS2 P35354 1/20 0.38
PKM P14618 3/20 0.38
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
XDH P47989 2/20 0.37
USP4 Q13107 1/20 0.36
USP7 Q93009 1/20 0.36
KDM4E B2RXH2 1/20 0.36
FDPS P14324 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21180762 0.82 MAPT (0.50) MAPTHPGDALDH1A1LMNATP53
SCHEMBL14355673 0.82 MAPT (0.50) MAPTMLYCDNPSR1HPGDALDH1A1
SCHEMBL20086468 0.77 MAPT (0.45) MAPTALDH1A1LMNAPKMTP53
SCHEMBL22808234 0.77 MAPT (0.45) MAPTMAPK1KDM4E
SCHEMBL20086406 0.76 MAPT (0.44) MAPTNPSR1ALDH1A1LMNAKDM4E
SCHEMBL15331363 0.76 HDAC8 (0.43) MAPTALDH1A1PKMUSP4USP7
SCHEMBL4443226 0.74 MLYCD (0.53) MAPTMLYCDNPSR1HPGDBRD4
SCHEMBL13702157 0.74 CREBBP (0.50) MAPTMLYCDHPGDBRD4CYP1A2
SCHEMBL20086452 0.73 MAPT (0.46) MAPTHPGDCYP1A2CYP2C19ALDH1A1
SCHEMBL20086597 0.73 MAPT (0.42) MAPTMLYCDHPGDALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10869934-B2 Antiproliferative compounds and conjugates made therefrom BRISTOL-MYERS SQUIBB COMPANY (US) 2020-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10869934-B2 Antiproliferative compounds and conjugates made therefrom MKI67, HDGF, PCLAF MAPT 3696/4885MLYCD 3756/4885NPSR1 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.